Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Approves H Share Repurchase Plan Up To RMB100 Mln
19/08/2026 16:58
BRIEF-Hangzhou Jiuyuan Genetic Biopharmaceutical Approves H Share Repurchase Plan Up To RMB100 Mln Aug 19 (Reuters) - Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd 2566.HK:
APPROVES H SHARE REPURCHASE PLAN OF UP TO RMB100 MILLION UNTIL MANDATE EXPIRATION
Further company coverage: 2566.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hangzhou Jiuyuan Genetic Biopharmaceutical
See all newsBrief: Hangzhou Jiuyuan Genetic Biopharmaceutical Approves H Share Repurchase Plan Up To RMB100 Mln
Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Says JY54 Injection Obtains NMPA Approval To Conduct Clinical Trials In China
Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Says JY47 Injection IND Application Obtains Clinical Trial Approval From NMPA
Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Says Marketing Application For Jikeqin Accepted By NMPA
Novo Nordisk cuts price of weight-loss drug Wegovy in China (updated)